Sign In
Buy SNY
$43.75
-0.230 (-0.523%)
At Close: Jul 21, 2026
3 Reasons Growth Investors Will Love Sanofi (SNY)
02:26pm, Monday, 17'th Apr 2023
Sanofi (SNY) possesses solid growth attributes, which could help it handily outperform the market.
SNY vs. LLY: Which Stock Is the Better Value Option?
12:56pm, Monday, 17'th Apr 2023
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Sanofi (SNY) or Eli Lilly (LLY). But which of these two companies is the best option for those lookin
4 Low Price-to-Sales Stocks to Get the Best of the Market
09:08am, Monday, 17'th Apr 2023
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like SNY, MFIN, PAA and KBH hold promise.
3 Healthcare Dividend Payers With Big Price Growth
07:11am, Friday, 14'th Apr 2023
You don't see financial TV channels dedicated to minute-by-minute coverage of dividend yield or increases, but for investors in companies like Sanofi (NASDAQ: SNY), AstraZeneca plc (NASDAQ: AZN), and
2 Top Healthcare Stocks Defying the Bear Market
08:10am, Friday, 07'th Apr 2023
The demand for medical product distribution is set to grow and McKesson is the clear leader of the industry. Sanofi's stacked product portfolio and pipeline should power double-digit annual earnings g
Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity?
05:48am, Thursday, 30'th Mar 2023
Dupixent's recent clinical data suggest it is a viable treatment option for adult patients with chronic obstructive pulmonary disease (COPD). The medicine could top $3 billion in annual revenue for Sa
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
01:26pm, Monday, 27'th Mar 2023
Shares of Sanofi (NASDAQ: SNY) were up 10.20% the week ended March 24, while Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) finished with a gain of 9.68%, following promising news about the companies'
Regeneron, Sanofi Look for Billions From COPD Drug
10:00am, Saturday, 25'th Mar 2023
The companies said Dupixent showed positive results in a late-stage study of current or former smokers with the killer disease.
Could This Label Expansion Be a Growth Catalyst for Sanofi Stock?
08:43am, Saturday, 25'th Mar 2023
Dupixent was proven to be effective at treating a condition that causes chronic hives. The indication could generate $600 million in annual revenue for Sanofi and Regeneron to share.
Is Sanofi Stock a Buy Now?
07:15am, Saturday, 25'th Mar 2023
Sanofi is reducing the price of its most important insulin product. A pending acquisition could help pick up the slack in diabetes care.
Biotech Growth Stock Soars To New Highs On Lung Disease Breakthrough
02:17pm, Friday, 24'th Mar 2023
Regeneron is scaling new highs after a lung disease breakthrough and analyst upgrade. The post Biotech Growth Stock Soars To New Highs On Lung Disease Breakthrough appeared first on Investor's Busines
ETFs in Focus on Sanofi and Regeneron's COPD Drug Data
09:12am, Friday, 24'th Mar 2023
Shares of drugmakers Sanofi and Regeneron surged more than 6% on Mar 23 on COPD drug data.
Sanofi (SNY) Moves 6.0% Higher: Will This Strength Last?
04:36am, Friday, 24'th Mar 2023
Sanofi (SNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Sanofi's (SNY) Dupixent Meets Goal in Pivotal COPD Study
03:14pm, Thursday, 23'rd Mar 2023
Sanofi (SNY) and partner Regeneron's (REGN) Dupixent led to a 30% decline in exacerbations per a late-stage pivotal study on chronic obstructive pulmonary disease.
Sanofi, Regeneron shares pop more than 6% after data shows asthma drug Dupixent may also treat COPD
02:31pm, Thursday, 23'rd Mar 2023
Sanofi and Regeneron unveiled data on their jointly developed drug for a difficult-to-treat chronic lung disorder that analysts say "exceeded expectations."
